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It has been well established that T lymphocytes can be triggered by antigen
interacting with the T cell antigen receptor (TcR)' or by antibodies binding to
the associated structure CD3. Recent findings (1) suggest the existence of
alternative pathways ofT lymphocyte activation. Certain mAbs to the cell surface
molecule CD2 (T11, LFA-2) activate T lymphocytes. T lymphocyte activation is
dependent on the epitope recognized by the anti-CD2 mAb. mAbs to a number
of other surface antigens provide a costimulatory signal. mAbs to CD5 (Tp67)
(2) and CDw28 (Tp44) (3) augment T lymphocyte proliferation and IL-2 pro-
duction. In the presence of PMA, mAbs to Tp44 stimulate purified T lympho-
cytesdirectly (3). We report here that an mAb to the surface protein sialophorin
stimulates T lymphocyte proliferation in a manner similar to mAbs to CD3 and
CD2.
Sialophorin, previously called gpL115, was found to be deficient in quantity
and/or defective in lymphocytes ofpatients with the X-linked immunodeficiency
Wiskott-Aldrich syndrome (4-6). A molecule indistinguishable from sialophorin
of normal lymphocytes was purified to homogeneity from cells of the lympho-
blastoid cell line CEM (6, 7). Sialophorin of CEM cells consists of >50% carbo-
hydrate, primarily -100 0-linked units of sialic acid, galactose, and galactosa-
mine, and a single -520-amino-acid polypeptide chain rich in serine, threonine,
and proline (7, 8).
In this report, the mAb L10 which recognizes a surface epitope ofsialophorin
(6) was used to investigate the expression and the function of the molecule.
Fluorescent staining with mAb indicated that sialophorin is expressed on all cells
in the thymus and on a fraction of bone marrow and peripheral blood cells.
Functional studies demonstrate that L10 mAb triggers the proliferation of
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'Abbreviations used in this paper.
￿
FITC-GAM, fluorescein-conjugated goat F(ab')2 anti-mouse
antibody; TcR, T cell antigen receptor.
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peripheral blood T cells. T lymphocyte stimulation by L10 mAb is dependent
on the presence of monocytes. The possibility that sialophorin provides another
pathway of T lymphocyte activation is discussed.
Materials and Methods
Culture Medium.
￿
Cells were grown in RPMI 1640 (M.A. Bioproducts, Walkersville,
MD) with 10% heat-inactivated FCS, 100 U/ml penicillin, and 100 Ag/ml streptomycin
(all from Gibco Laboratories, Grand Island, NY), 10 mM Hepes (Sigma Chemical Co., St.
Louis, MO), and 25 AM 2-ME (Eastman Organic Chemicals, Rochester, NY). The long-
term cytolytic T lymphocyte (CTL) line was maintained in 10% human conditioned
medium.
IL-2-containing Human Conditioned Medium.
￿
IL-2-containing conditioned medium was
prepared as described (9) by culturing washed mononuclear cells isolated from platelet-
pheresis residue at 3 x 106/ml in RPMI 1640 with 3% FCS, 0.15% PHA (Bacto PHA-P;
Difco Laboratories, Inc., Detroit, MI), 2.8 AM indomethacin (Sigma Chemical Co.), 3 mM
lithiumchloride,and50 AM hydroxyurea(Sigma Chemical Co.). Theconditioned medium
was collectedafter 72 h and subjected to fractional precipitation with ammonium sulfate.
The 50-75% saturated ammonium sulfate fraction was dialyzed, filter-sterilized, and
stored at -20°C.
Cell-Surface Immunofuorescence.
￿
Cells were washed twice with PBS containing 2.5%
FCS and 0.02% sodium azide. In dual parameteranalysis, the cells were incubated on ice
for 30 min with excess fluorescein- and phycoerythrin-conjugated mAb. The cells were
washed three times, fixed in 1% paraformaldehyde and examined on a FACS I analyzer
(Becton Dickinson & Co., Mountain View, CA). In single parameter analysis, the cells
were incubated with mAbs, washed and incubated with a 1:10 dilution of fluorescein-
conjugated goat F(ab')2 anti-mouse IgG antibody (FITC-GAM, Tago, Burlingame, CA)
on ice for 30 minand were washed and fixed.
Proliferation Assay. Peripheral blood mononuclear cells were isolated by Fi-
coll/Hypaque centrifugation (Lymphocyte Separation Medium; Bionetics Laboratory
Products, Charleston, SC). Threefold dilutions of cells were cultured in triplicate in
round-bottom microtiter wells (Linbro Chemical Co., Hamden, CT). mAbs were added
at the start of the cell culture. The cells were pulsed with 1 ACi [- 'H]thymidine per well
for 24 h before harvestat 72, 96, or 120 h.
Treatmentwith mAbs and Complement.
￿
Peripheral blood or bone marrow mononuclear
cells isolated by Ficoll/Hypaque centrifugation were incubated at 2 x 10'/ml with 10
Ag/ml mAb on ice for 30 min. The cells were pelleted and incubated with rabbit
complement (Pel-Freeze Biologicals, Rogers, AR) at a 1:3 dilution for 1 h at 37°C and
then washed. The efficiency of complement lysis was assessed by trypan blue exclusion
and immunofluorescence analysis.
Monoclonal Antibodies. Hybridoma cells producing mAbs were grown as ascites in
BALB/c mice. The antisialophorin mAb L10 is an IgGl which recognizes native and
sialidase-treated sialophorin (6). MMA mAb recognizes the surface molecule MMA on
phagocytes (10). The mAbs defining cell surface molecules associated with T cell activa-
tion, 4172 (11) and TS2/7 (anti-VLA-1 ; reference 12), were used at a 1:200 dilution of
hybridoma ascites. Other mAbs were obtained as follows: OKT3, OKTI I (Ortho Phar-
maceutical, Raritan, NJ) and Leu-1, Leu-3a, Leu-8, Leu-11, Leu-12, Leu-15, Leu-M3,
anti-IL-2-R, and anti-HLA-DR (Becton Dickinson & Co.). Where indicated, IgG was
purified from ascites by protein A-Sepharose chromatography (13).
Preparation of F(ab')2 Antibodies.
￿
F(ab')2 fragments were prepared from purified IgG
as described (13). Briefly, 200 Al of papain-Sepharose (gift of Dr. S. Herrmann, Dana-
Farber Cancer Institute, Boston, MA) was activated with 50 mM cysteine hydrochloride
(Sigma Chemical Co.) for 30 min at 37 °C. Papain-Sepharose was washed and incubated
with purified mAb IgG for 6 h at 37'C. The resin was removedby centrifugation and Fc
fragmentsand intact IgG were separated from F(ab')2antibodies by Protein A-Sepharose
chromatography.L/0
MENTZER ET AL.
￿
1385
v
C Q
FIGURE 1 . Surface expression
of sialophorin on peripheral
blood mononuclear cells assessed
by dual parameter immunofluo-
rescence. Peripheral blood mono-
nuclear cells were stained with
FITC-conjugated L10 mAb (5
fag/ml). Phycoerythrin-conju-
gated mAb added at 5 Wg/ml for
the second parameter were: anti-
CD4 (Leu-3a), anti-CD8 (Leu-2),
anti-CD19 (Leu-12), anti-CD16
(Leu-11), anti-CD11 (Leu-15),
and Leu-M3.
Monocyte Purification.
￿
Leukocytes from plateletpheresis residues were washed in cul-
ture medium and fractionated by Ficoll/Hypaque centrifugation. The mononuclear cells
at 5 x 107/ml in culture medium were placed on a rocker for 30 min at 4°C. Aggregated
cells were isolated using unit gravity sedimentation (14). These cells were underlayered
with 3 ml cold FCS and harvested after 15 min of unit gravity sedimentation. The pelleted
cells were incubated at 107/ml in 75-cm' culture flasks at 37° C for 30 min. The adherent
cells were vigorously washed with culture medium. Culture medium containing 20% FCS
was added to the remaining adherent cells, which were harvested after culture for 12 h.
These purified monocytes were used to reconstitute autologous monocyte-depleted
PBMC in proliferation assays.
Results
Distribution of Sialophorin.
￿
Previous studies (6) used surface radioiodination
to demonstrate sialophorin expression on the surface of lymphocytes and CEM
lymphoblastoid cells. To further investigate the distribution of sialophorin, we
performed dual-parameter immunofluorescence analysis of peripheral blood
cells. Staining of freshly isolated blood mononuclear cells with fluorescein con-
jugates of the antisialophorin mAb L10 demonstrated that sialophorin is ex-
pressed on both CD4+ (T4, Leu-3a) and CD8' (T8, Leu-2) cells (Fig. 1) as well
as all CD2+ (TI 1, Leu-5) and CD5+ (TI, Leu-1) Tlymphocytes(data notshown).
L10 staining was also observed on some peripheral B lymphocytes defined by
the B cell mAb Leu-12 (anti-CD19) (Fig. 1). Thus, staining with L10 indicates
that sialophorin is expressed on all Tlymphocytes and on a subset ofB lympho-
cytes.
In addition, L10 mAb stained 50% of CD11' (Leu-15) peripheral blood
mononuclear cells (Fig. 1). The CD11 antigen, defined by Leu-15/OKM 1/Mo1
mAb, is expressed on monocytes, NK cells, and some T lymphocytes (15, 16).
Sialophorin expression on NK cells is indicated by the detection of a population
of L10+ cells that stained with an mAb to the NK marker CD16 (Leu-11 mAb,
anti-Fc receptor) (Fig. 1). Peripheral blood mononuclear cells that stained with
the monocyte marker mAb LeuM3 did not stain with L10 (Fig. 1).
L10 mAb staining indicated that sialophorin is expressed on virtually all1386 ANTISIALOPHORIN ANTIBODY ACTIVATES T LYMPHOCYTES
TABLE I
Surface Expression ofSialophorin
Cells were incubated with LIO mAb followed by FITC-labeled second
antibody. Theextent ofbindingof mAbis expressedas mean fluorescence
intensity(MFI)aftersubtraction ofblankfluorescence (cells without mAb;
3.7-6.4 MFI). Thymocytes were obtained from donors <1 yr oldundergo-
ing cardiac surgery. Bone marrow cells obtained from normal adult
volunteers were depleted of T cells by treatment with Leu-1 mAb (anti-
CD5) and complement.
TABLE II
Effect ofL10 mAb on Cytolytic Activity
Cytolytic activity is expressed as percent specific "Cr release in 4 h. The
NK effector cells, freshly isolated peripheral blood mononuclear cells,
were tested at 100:1 against K562 target cells and the CTL line at 12:1
againstJY cells (HLA-A2; B7; DR4,6). The CTL effector line wasa long-
term line maintained by weekly stimulation with irradiated JY cells and
conditioned medium containing IL-2.
Tymocytes (Table I). To investigate sialophorin expression on bone marrow
cells, the total population was depleted of T cells by treatment with Leu-1 mAb
(anti-CD5) and complement. The residual bone marrow cells were CD2- and
CD3-. However, 29% of the residual bone marrow cells were L10+, indicating
expression ofsialophorin (Table I).
L10 mAb did not stain erythrocytes or other mesenchymal cells, such as
primary fibroblasts and a rhabdomyosarcoma cell line RD (data not shown).
L10 mAb Stimulates the Proliferation of T Lymphocytes.
￿
The function ofseveral
surface molecules, including LFA-1, CD4, and CD8, was demonstrated by the
ability of appropriate mAbs to inhibit CTL and NK function . In the initial
functional evaluation ofsialophorin, it was observed that, rather than inhibiting
CTL and NK function, L10 mAb augmented cytolytic T cell activity (Table II).
The marginal stimulation ofTcells and NK cells in cytotoxicity assays suggested
that L10 mAb might be stimulatory for T lymphocytes.
Purified L10 mAb was compared with mAbs recognizing other T cell surface
antigens for their ability to stimulate T cell proliferation. In multiple experi-
ments, mAbs recognizing the T cell antigens sialophorin and CD3 stimulated
>10-fold increase in ['H]thymidineincorporation. In contrast, mAbsrecognizing
CD2, CD4, CD5, CD8, and Leu-8 antigens did not stimulate [sH]thymidine
L10 mAb (rig/ml)
Cytolytic
NK effector cells
activity
CTL effector cells
0 52 38
5 60 47
10 61 55
30 62 56
Cells Positive MFI
Thymocytes 92 29.9
Bone marrow 29 22.5
PBMCs 62 33.0M 0
U
Media OKT3 LIO Leu-I Leu-2 Leu-3a Leu-8 OKTII
Monoclonal Anlibodles
mAb (ng/ml)
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FIGURE 2.
￿
Specificity of L10 mAb-stimu-
lated proliferation. Peripheral blood mono-
nuclear cellsat 3 X 105per well were incu-
bated with medium alone or 5 kg/ml of
OKT3 (anti-CD3); L10 (anti-sialophorin);
Leu-1 (anti-CD5); Leu-2(anti-CD8); Leu-3a
(anti-CD4); Leu-8; and OKTI I (anti-CD2)
mAbas indicated. The cultures were pulsed
with ['H]thymidine (1 WCi/well) for 24 h
before harvest at 72 h.
FIGURE 3.
￿
Time course of L10 mAb-stimulated pro-
liferation. Peripheral blood mononuclear cells at 3 X
105 per well were incubated with 500 ng/ml of L10
mAb (0), OKT3 mAb (A), or with medium (0). The
cells were harvestedat theindicated times after a 24-
hincubation with ['H]thymidine (1 ACi/well).
FIGURE 4.
￿
Titration of purified L10 and
OKT3 mAb. Variousconcentrations of pu-
rified L10 IgGor L10 F(ab')yorOKT3 IgG
were cultured with 3 X 10'peripheral blood
mononuclear cells per well. The cultures
were pulsed with ['H]thymidine (1 uCi/well)
for24 h before being harvestedat 72 h.
incorporation (Fig. 2). L10 mAb was comparable to anti-CD3 mAb in its ability
to stimulate proliferation. Both L10 mAb and anti-CD3 mAbstimulated maximal
[sH]thymidine incorporation at 72 h (Fig. 3). The concentration of L10 mAb
required for optimal proliferation was 100 ng/ml. Anti-CD3 mAb was more
efficient than L10 mAb at stimulating proliferation in the range of 10-100
ng/ml (Fig. 4).
The distribution of sialophorin molecules indicated that L10 could be stimu-
lating NK cells or B cells, in addition to Tcells. To identify the peripheral blood
mononuclear cells stimulated by L10, we used mAbs and complement to deplete
various populations. Treatment ofperipheral blood mononuclear cells with the1388
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TABLE III
Monocyte Dependence ofL10 mAb-Stimulated T Cell Proliferation
Discussion
['H]Thymidine incorporation (24-hpulse) is presentedas cpm X 10'assessed after 72 h
ofculture.The mean oftriplicate values is shown; variance was usually <_10%. Depletion
of T cells by treatment with Leu-1 mAb and complement was >_98% complete, as
demonstrated by Leu-1 mAb fluorescent staining. Monocyteswere depleted using MMA
mAb and complement. Where indicated, 10% purified monocytes were added to the
monocyte-depleted cultures. Intact OKT3 and L10 mAbwere at 100 ng/ml.
pan-T cell mAb Leu-1 (anti-CD5) and complement completely abrogated the
proliferative response to L10 mAb, indicating that peripheral blood T lympho-
cytes were responsible for [sH]thymidine incorporation (Table III, Exp. A).
Similar results were obtained when a combination of anti-CD3 and anti-CD2
mAb and complement were used for cell depletion (data not shown) .
Monocyte Dependence of L10-stimulated Proliferation.
￿
When monocytes were
depleted from peripheral blood mononuclear cells by treatment with MMA mAb
and complement, L10-stimulated proliferation was not observed (Table III, Exp.
B), indicating that monocytes are required for stimulation of T lymphocytes by
L10 mAb. This finding suggested that monocytes are needed for monokine
production and/or Fc receptor binding of L10 mAb. F(ab')2 fragments of L10
mAb were found to be 50-fold less effective than intact L10 IgG in stimulating
T cell proliferation (Fig. 4), suggesting that an important contribution of mon-
ocytes is binding of intact L10 mAb via the Fc receptor. The addition of
supernatants from PHA-activated mononuclear cells did not restore L10-de-
pendent proliferation to monocyte-depleted T cells (data not shown), suggesting
that the monocyte dependence is not due solely to a requisite monokine.
Expression ofActivation Antigens after L10 Stimulation.
￿
To further investigate
the activationofT lymphocytesby L10, the surface expression ofTcellactivation
antigens was evaluated 5 d after stimulation. The activation antigens HLA-DR,
IL-2-R, and 4F2 were induced by L10 mAb, by the anti-CD3 mAb OKT3, and
by PHA (Table IV). None of these agents induced the expression of the late
activation antigen VLA-1 . Thus, the induction of early activation antigens by
L10 mAb is similar to the induction by anti-CD3 mAb. The anti-CD3 mAb
OKT3 effectively modulated the CD3 antigen. In contrast, no modulation of
the sialophorin antigen was observed at 5 d.
Fluorescent staining with the mAb L10 demonstrated that the heavily glyco-
sylatedsurfaceprotein sialophorin is expressedon all T lymphocytes inperipheral
Exp. Responding cells
['H]Thymidine
No mitogen
incorporation
OKT3 mAb
(cpm X 10-')
L10mAb
A PBMC 0.9 34.2 39.3
PBMC, T-depleted 0.3 0.9 0.8
B PBMC 1.4 47 .1 41 .7
PBMC, monocytes depleted 3.7 7.5 12.8
PBMC, monocytes depleted, 2.2 58 .4 66.1
monocytes addedMENTZER ET AL.
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TABLE IV
Induction of Expression ofActivation Antigens
Peripheral bloodmononuclear cellswere incubated with PHA-P(3,ug/ml),
OKT3 mAb (100 ng/ml), and L10 mAb (100 ng/ml) for 5 d. Expression
of surface antigens is presented as the MFI of cells stained with the
detecting mAb and FITC-GAM with blank fluorescence (cells without
mAb) substracted. Parallel cell cultures that were washed twice48 hbefore
harvest to remove surface-bound antibody gave similar results (data net
shown).
blood and on a subpopulation ofB lymphocytes. Sialophorin is also expressed on
virtually all thymocytes and some bone marrow cells. Functional studies demon-
strated that L10 mAb stimulates the proliferation of peripheral blood T cells.
The time course and magnitude of mAb-induced T lymphocyte proliferation
are similar for sialophorin and CD3. In addition, both molecules require the Fc
portion of the antibody for stimulation. Either substitution of F(ab')2 mAb or
depletion of monocytes significantly diminished the proliferative response ofT
lymphocytes to L10 mAb. The Fc region may be required for binding the mAb
to monocytes and presenting it to T cells. As suggested by others (17, 18), mAb
binding by the monocyte Fc receptor may be required to facilitate clustering or
aggregation ofthe corresponding surface antigen.
Surface expression of the activation antigens HLA-DR, IL-2-R, and 4F2
provided an additional measure of T cell activation. The magnitude and time
course of expression of activation antigens was similar for cells stimulated by
PHA, anti-CD3 mAb, and L10 mAb. The induction of IL-2-R by all three agents
suggests a common pathway dependent on IL-2 growth factor.
The failure of the dual-parameter mAb staining experiments to detect sialo-
phorin on peripheral blood Leu-M3+ cellsis not readilyexplainable since another
study detected sialophorin expression on isolated monocytes using the technique
ofimmunoblotting with L10 mAb (19). Immunoblotting analysis with L10 mAb
also demonstrated sialophorin expression on blood neutrophils, lymphocytes,
and platelets (19).
The chemical characteristics of the sialophorin molecule are similar to those
of the rat surface molecule defined by W3/13 mAb (20, 21). Like sialophorin,
W3/13 antigen (also called leukocyte sialoglycoprotein) is a heavily glycosylated
single-chain polypeptide rich in serine, threonine, and proline with multiple 0-
linked carbohydrate unitsofsialic acid, galactose, and galactosamine (21). W3/13
mAb was found to stain all thymocytes, T (but not B) lymphocytes, bone marrow
neutrophils, and brain cells (20).
Highly glycosylated surface proteins resembling sialophorin have been de-
Antigen expression in response to
Surface antigen
(detecting mAb)
None
activating
PHA
agents
OKT3 L10
Sialophorin (L10) 33.8 56.2 41 .9 33.1
CD3 (OKT3) 30.0 33.9 11 .9 34.7
IL-2-R (anti-IL-2-R) 4.1 15.0 12.0 21 .0
HLA-DR (anti-HLA-DR) 3.5 34.2 11 .6 24.1
4F2 (anti-4F2) 12.7 47.6 61 .4 73.7
VLA-1 (TS2/7) 11.7 12.2 15.7 12.71390
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tected by others on human lymphoid cells (reviewed in references 7 and 8).
Expression of the human sialophorin-like molecule L-LSGP was detected by
fluorescent mAb staining on most thymocytes, virtually all T4' and T8+ periph-
eral blood lymphocytes, and 25% of circulating B lymphocytes, but not on
peripheral blood monocytes, neutrophils, and platelets (22).
The association ofsialophorin with stimulation of T lymphocytes, on the one
hand, and, on the other hand, the defect of sialophorin in lymphocytes of
Wiskott-Aldrich syndromepatients suggest intriguing possible relationships. The
Wiskott-Aldrich syndrome is an X-linked trait characterized clinically by both
lymphocyte and platelet dysfunction. Successful bone marrow transplantation
indicates that the defect resides in lymphohematopoietic cells (23-26). Structural
correlates ofthe Tcell functional defect have been identified in Wiskott-Aldrich
syndrome. At the cellular level, gross abnormalities of lymphocyte surface
architecture were identified (27) and, at the molecular level, lymphocytes from
Wiskott-Aldrich patients were found to be deficient in sialophorin and/or to
express defective molecules (5, 6). The deficiency/defect of the sialophorin
molecule in Wiskott-Aldrich syndrome cells and the capacity of sialophorin to
function in normal T cell proliferation as reported here suggest the involvement
ofsialophorin in the pathogenesis of the Wiskott-Aldrich syndrome.
In conclusion, sialophorin has the capacity to function in T cell activation. The
antisialophorin mAb L10 stimulates T cell proliferation in a manner similar to
anti-CD3 mAb. Remaining questions concern the identity of the putative phys-
iological ligand for sialophorin, the mode oftransmembrane signaling by sialo-
phorin, and the role ofsialophorin defects in the Wiskott-Aldrich syndrome.
Summary
The mAb L10 was used to determine the distribution and the function of
sialophorin, the heavily glycosylated surface molecule that is deficient/defective
in lymphocytes of patients with the X-linked immunodeficiency Wiskott-Aldrich
syndrome. Dual-parameter FACS analysis indicated that sialophorin is expressed
on CD4+ and CD8+ lymphocytes, on a subpopulation of peripheral blood B
lymphocytes, on all thymocytes, and on a subpopulation of bone marrow cells.
Functional studies demonstrated that L10 mAb stimulates the proliferation of
peripheral blood T lymphocytes as measured by stimulation of ['H]thymidine
incorporation. The time course and magnitude of increased [sH]thymidine
incorporation by T lymphocytes in response to L10 mAb paralleled that induced
by anti-CD3 mAb. Effective stimulation was dependent on the presence of
monocytes and the Fc portion of L10 mAb. Stimulation of lymphocytes by L10,
like stimulation by anti-CD3 mAb, involves increased expression of 4F2, HLA-
DR, and IL-2-R . These observations suggest that sialophorin functions in Tcell
activation.
Receivedfor publication 24 November 1986.
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